Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
ABS-201 proof-of-concept readouts are expected in December 2026 and early 2027 as quarterly research spending increases.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Absci (Nasdaq: ABSI) reported a third-quarter 2026 net loss of $33.3 million while continuing clinical development of ABS-201. Revenue fell to $304,000 from $378,000 a year earlier, and net loss widened from $28.706 million. Research and development expenses rose to $23.572 million from $19.249 million. Loss per share narrowed to $0.19 from $0.20.
Cash, cash equivalents and marketable securities totaled $173.7 million at September 30, versus $201.1 million at June 30. Absci expects these funds to support operating plans into the second half of 2028. It anticipates ABS-201 hair-loss trial data at 13 weeks in December 2026 and at 26 weeks in early 2027. The planned Phase 2 endometriosis trial is expected to start in mid-2027, subject to protocol finalization and regulatory clearance. Absci also appointed Gerry Muhle as Chief Commercial Officer.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 2 endometriosis trial planned for mid-2027, with approximately 150 patients from approximately 10 or more countries.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Operating funds are expected to last into the second half of 2028, based on current projections.
- Minor point. Forward-looking: it has not happened yet and may not happen.ABS-201 hair-loss trial continues dosing; Absci anticipates 13-week data in December 2026 and 26-week data in early 2027.
- Minor pointEarlier blinded single-dose ABS-201 cohorts showed favorable safety data; study medication appeared well tolerated.
- Minor pointQuarterly loss per share narrowed to $0.19 from $0.20 year over year.
4 minor points
- Minor pointNine-month loss per share narrowed to $0.60 from $0.65 year over year.
- Minor pointQuarterly depreciation and amortization fell to $2.688 million from $2.842 million year over year.
- Minor pointNine-month depreciation and amortization fell to $8.112 million from $8.914 million year over year.
- Minor pointLong-term debt fell to $61,000 at September 30, 2026, from $873,000 at December 31, 2025.
Negative
- Moderate pointQuarterly net loss widened to $33.300 million from $28.706 million year over year.
- Moderate pointQuarterly research and development expenses increased to $23.572 million from $19.249 million year over year.
- Moderate pointCash, equivalents and marketable securities fell to $173.7 million at September 30 from $201.1 million at June 30.
- Moderate pointQuarterly weighted-average shares increased to 171,799,223 from 143,769,552 year over year.
- Minor pointQuarterly revenue declined to $304,000 from $378,000 year over year.
6 minor points
- Minor pointQuarterly selling, general and administrative expenses increased to $9.038 million from $8.441 million year over year.
- Minor pointNine-month net loss widened to $96.109 million from $85.621 million year over year.
- Minor pointNine-month revenue declined to $837,000 from $2.150 million year over year.
- Minor pointNine-month research and development expenses increased to $65.463 million from $56.071 million year over year.
- Minor pointNine-month selling, general and administrative expenses increased to $27.260 million from $26.441 million year over year.
- Minor pointSTORYLINE recruitment remains subject to protocol finalization and regulatory clearance; dose levels depend on HEADLINE data.
Key Figures
- Revenue
- $0.3 million vs. $0.4 million
- Three months ended September 30, 2026 vs. 2025
- Research and development expenses
- $23.6 million vs. $19.2 million
- Three months ended September 30, 2026 vs. 2025
- Net loss
- $33.3 million vs. $28.7 million
- Three months ended September 30, 2026 vs. 2025
- Cash, cash equivalents and marketable securities
- $173.7 million
- As of September 30, 2026; compared with $201.1 million as of June 30, 2026
- Projected operating runway
- Into the second half of 2028
- Based on the company's current projections
- Interim proof-of-concept data
- 13 weeks; anticipated in December 2026
- ABS-201 HEADLINE trial for pattern hair loss
- Full proof-of-concept data
- 26 weeks; anticipated in early 2027
- ABS-201 HEADLINE trial for pattern hair loss
- Planned STORYLINE enrollment
- Approximately 150 patients
- Phase 2 endometriosis trial; subject to protocol finalization and regulatory clearance
Previous Earnings Reports
-
Interim HEADLINE safety findings and estimated half-life contextualized ABS-201's current proof-of-concept milestones.
-
Prior Q3 financial benchmarks and ABS-201 development timing provide direct year-over-year context.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
multiple ascending dose medical
proof-of-concept medical
half-life medical
placebo-controlled medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month
Announced preliminary details for Phase 2 STORYLINE™ trial of ABS-201 for endometriosis
Appointed former Galderma executive Gerry Muhle as Chief Commercial Officer
VANCOUVER, Wash. and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended September 30, 2026.
“As we approach our first look at proof-of-concept data for ABS-201 next month, followed by full data early next year, we are excited for the opportunity to potentially demonstrate our program's ability to stimulate hair regrowth in a convenient and durable way,” said Sean McClain, Founder and CEO. “As ABS-201 progresses through the clinic, we have begun building our commercial infrastructure to support this and potential future programs. In line with that strategy, we are thrilled to be welcoming Gerry Muhle to Absci as our Chief Commercial Officer, whose experience we believe will position ABS-201 and our expanding program pipeline for success.”
Recent Highlights
- Continuing to dose participants with pattern hair loss (PHL) in multiple ascending dose (MAD) portion of the HEADLINE trial. Absci anticipates reporting 13-week interim proof-of-concept data from this study in December 2026 and full 26-week proof-of-concept data in early 2027.
- Announced additional details for Absci's planned global, multi-center Phase 2 STORYLINE clinical trial evaluating ABS-201 for endometriosis. Absci anticipates initiation of this Phase 2 clinical trial in mid-2027.
- Appointed former Galderma executive Gerry Muhle as Chief Commercial Officer. Muhle brings over 25 years of experience across pharma, aesthetics, and consumer brands, and joins Absci as the company continues to build its commercial infrastructure to support its wholly-owned programs.
Prolactin (PRL) Program Portfolio
- ABS-201 for Pattern Hair Loss: ABS-201, currently undergoing Phase 1/2a studies, is being developed for pattern hair loss (PHL). Absci believes that ABS-201, if successfully developed and approved, could provide a significant new category of PHL treatment that offers the potential for durable hair growth with a convenient administration profile. In June, Absci announced positive interim Phase 1 data from the HEADLINE trial, demonstrating that the study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts. Additionally, the estimated half-life of at least 65 days supports the potential for ABS-201's targeted dosing interval of two or three injections over a six-month period. Absci anticipates reporting 13-week interim proof-of-concept data in December 2026 and full 26-week proof-of-concept data in early 2027.
- ABS-201 for Endometriosis: Endometriosis is a condition that impacts a large, underserved patient population with significant unmet medical need and poor standard of care. Endometriosis is prevalent in up to
10% of women worldwide, including an estimated 9 million women in the U.S., and there is currently no FDA-approved disease-modifying therapy. ABS-201 for endometriosis represents a novel non-sex steroid hormone mechanism, with potential to be disease-modifying, act on both pain and lesion growth, and offer an improved safety profile. With the safety, tolerability, and PK data being generated for ABS-201 in the company’s ongoing HEADLINE trial, Absci anticipates initiation of the Phase 2 STORYLINE trial for endometriosis in mid-2027. The planned Phase 2, double-blind, randomized, placebo-controlled trial would assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period. Efficacy endpoints would include reductions in dysmenorrhea and non-menstrual pelvic pain as reported via patient-reported measures. For this trial, Absci anticipates recruiting approximately 150 patients from approximately 10 or more countries, subject to protocol finalization and regulatory clearance. Absci is designing STORYLINE as a dose-ranging trial, anticipating testing two or three dose levels that will be confirmed following review of HEADLINE data. - ABS-202 for Undisclosed I&I Indication: ABS-202 is an anti-PRLR antibody in preclinical development for an undisclosed I&I indication.
Other Internal Pipeline Programs and Partnerships
Absci continues to advance its ongoing drug creation partnered programs, as well as partnering discussions for other internal programs at various stages of preclinical and clinical development.
Recent Publications, Presentations, and Abstracts
Accepted Presentations and Abstracts
- Third Barcelona Hair Meeting 2026: “ABS-201-Mediated Prolactin Receptor Inhibition Promotes Hair Growth in Androgen-Sensitive Male Scalp Skin by Prolonging Anagen, Stimulating Hair Shaft Production, and Activating Stem Cells”
- American Society for Reproductive Medicine (ASRM) 2026: “Prolactin Receptor Blockade With Anti-Prolactin Receptor Antibody (Anti-PRLR Ab) Relieves Pain and Inflammation in a Homologous Transplant Mouse Model of Endometriosis”
- New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium 2026: “FDA Studies on Hair Growth: Extended Release Minoxidil and Prolactin Receptor Inhibition”
Third Quarter 2026 Financial Results
Revenue was
Research and development expenses were
Selling, general, and administrative expenses were
Net loss was
Cash, cash equivalents, and marketable securities as of September 30, 2026 were
Based on the company's current projections, Absci believes its cash, cash equivalents, and marketable securities will be sufficient to fund its operating plans into the second half of 2028.
Webcast Information
Absci will host a conference call to discuss its third quarter 2026 business updates and financial and operating results on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. A webcast of the conference call can be accessed at investors.absci.com. The webcast will be archived and available for replay for at least 90 days after the event.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These statements include forward-looking statements regarding ABS-201 and our other pipeline programs, including: the conduct and timing of our Phase 1/2a HEADLINE™ trial of ABS-201 in pattern hair loss, with interim proof-of-concept data expected in the fourth quarter of 2026 and full proof-of-concept data in early 2027; potential advancement of ABS-201 to Phase 3 development, including an expedited path directly from Phase 1/2a; a planned Phase 2 trial of ABS-201 in endometriosis beginning in 2027; the anticipated product profile and target product profile of ABS-201; planned engagement with the FDA regarding development strategy; the market opportunity and commercial prospects for ABS-201; and the capabilities and anticipated benefits of our ATLAS platform and other platform technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in Absci Corporation’s most recent annual report on Form 10-K and in any other subsequent filings made by Absci Corporation with the U.S. Securities and Exchange Commission. Additional information regarding the risks and uncertainties that could affect our forward-looking statements is set forth in our most recent Annual Report on Form 10-K and subsequent documents and reports filed by Absci from time to time with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
Investor Contact:
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com
Media Contact:
press@absci.com
| Absci Corporation Unaudited Condensed Consolidated Statements of Operations | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| (In thousands, except for share and per share data) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenues | ||||||||||||||||
| Partner program revenue | $ | 304 | $ | 378 | $ | 837 | $ | 2,150 | ||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 23,572 | 19,249 | 65,463 | 56,071 | ||||||||||||
| Selling, general and administrative | 9,038 | 8,441 | 27,260 | 26,441 | ||||||||||||
| Depreciation and amortization | 2,688 | 2,842 | 8,112 | 8,914 | ||||||||||||
| Total operating expenses | 35,298 | 30,532 | 100,835 | 91,426 | ||||||||||||
| Operating loss | (34,994 | ) | (30,154 | ) | (99,998 | ) | (89,276 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest expense | (2 | ) | (45 | ) | (22 | ) | (180 | ) | ||||||||
| Other income, net | 1,714 | 1,597 | 3,987 | 4,066 | ||||||||||||
| Total other income, net | 1,712 | 1,552 | 3,965 | 3,886 | ||||||||||||
| Loss before income taxes | (33,282 | ) | (28,602 | ) | (96,033 | ) | (85,390 | ) | ||||||||
| Income tax expense | (18 | ) | (104 | ) | (76 | ) | (231 | ) | ||||||||
| Net loss | $ | (33,300 | ) | $ | (28,706 | ) | $ | (96,109 | ) | $ | (85,621 | ) | ||||
| Net loss per share: Basic and diluted | $ | (0.19 | ) | $ | (0.20 | ) | $ | (0.60 | ) | $ | (0.65 | ) | ||||
| Weighted-average common shares outstanding: Basic and diluted | 171,799,223 | 143,769,552 | 160,804,654 | 132,114,850 | ||||||||||||
| Absci Corporation Unaudited Condensed Consolidated Balance Sheets | ||||||||
| September 30, | December 31, | |||||||
| (In thousands, except for share and per share data) | 2026 | 2025 | ||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 13,359 | $ | 20,025 | ||||
| Marketable securities | 160,370 | 124,267 | ||||||
| Prepaid expenses and other current assets | 8,164 | 5,281 | ||||||
| Total current assets | 181,893 | 149,573 | ||||||
| Operating lease right-of-use assets | 2,146 | 2,914 | ||||||
| Property and equipment, net | 14,759 | 20,860 | ||||||
| Intangibles, net | 39,334 | 41,514 | ||||||
| Restricted cash, long-term | 1,059 | 1,053 | ||||||
| Other long-term assets | 383 | 383 | ||||||
| TOTAL ASSETS | $ | 239,574 | $ | 216,297 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 15,625 | $ | 19,348 | ||||
| Long-term debt | 61 | 873 | ||||||
| Operating lease obligations | 2,085 | 1,805 | ||||||
| Deferred revenue | 1,090 | 739 | ||||||
| Total current liabilities | 18,861 | 22,765 | ||||||
| Operating lease obligations, net of current portion | 1,142 | 2,624 | ||||||
| Deferred revenue, long-term | — | 436 | ||||||
| Other long-term liabilities | 894 | 1,023 | ||||||
| TOTAL LIABILITIES | 20,897 | 26,848 | ||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 17 | 15 | ||||||
| Additional paid-in capital | 940,068 | 813,627 | ||||||
| Accumulated deficit | (720,893 | ) | (624,784 | ) | ||||
| Accumulated other comprehensive income (loss) | (515 | ) | 591 | |||||
| TOTAL STOCKHOLDERS' EQUITY | 218,677 | 189,449 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 239,574 | $ | 216,297 | ||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Absci report ABS-201 hair-loss proof-of-concept results?
Absci anticipates 13-week interim proof-of-concept data in December 2026 and full 26-week proof-of-concept data in early 2027. Participants with pattern hair loss continue to receive treatment in the multiple ascending dose portion of the HEADLINE trial.
How long does Absci expect its cash to fund operations?
Absci expects its cash, cash equivalents and marketable securities to fund operating plans into the second half of 2028, based on current projections. These holdings totaled $173.7 million at September 30, 2026, compared with $201.1 million at June 30, 2026.
How will Absci's STORYLINE endometriosis trial measure ABS-201 efficacy?
The planned STORYLINE trial would measure reductions in menstrual pain and non-menstrual pelvic pain using patient-reported measures. The double-blind, randomized, placebo-controlled study would enroll participants with surgically diagnosed endometriosis and moderate to severe associated pain after a run-in period. Absci anticipates testing two or three dose levels, to be confirmed after reviewing HEADLINE data.